🇺🇸 FDA
Patent

US 9630956

Compounds useful as inhibitors of ATR kinase

granted A61PA61P35/00A61P43/00

Quick answer

US patent 9630956 (Compounds useful as inhibitors of ATR kinase) held by Vertex Pharmaceuticals Incorporated expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
36
CPC classes
A61P, A61P35/00, A61P43/00